drugset / Trial / NCT00697593
ChangE From Any Systemic psoriasiS therapY to Raptiva
NaSingle-groupOpen-labelTreatment
Summary
To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or phototherapy dose.
Timeline
- Start
- 2008-01
- Primary completion
- 2009-04
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | efalizumab | Monoclonal antibody | 1 mg/kg | — |